羟氯喹在IgA肾病中的临床研究进展  

Clinical research progress of hydroxychloroquine in IgA nephropathy

作　　者：王晔[1,2] 杨婷 王路路 张海霞[1] WANG Ye;YANG Ting;WANG Lu-lu;ZHANG Hai-xia(Department of Pharmacy,Drum Tower Hospital,China Pharmaceutical University,Nanjing 210008;School of Basic Medicine and Clinical,China Pharmaceutical University,Nanjing 210009)

机构地区：[1]中国药科大学南京鼓楼医院药学部,南京210008 [2]中国药科大学基础医学与临床药学学院,南京210009

出　　处：《中南药学》2021年第11期2371-2376,共6页Central South Pharmacy

基　　金：江苏省研究型医院学会精益化用药科研基金资助(No.JY202013);中国毒理学会临床毒理专项研究课题(No.CST2019CT305)。

摘　　要：羟氯喹是在氯喹的基础上开发的4-氨基喹啉类的新型抗疟药,目前有研究表明羟氯喹可以作为新的辅助免疫调节剂有效地降低IgA肾病患者的蛋白尿。IgA肾病是一组免疫病理特征以肾小球系膜区IgA沉积为主的临床综合征,由于其发病机制比较复杂,所以并没有特定的治疗药物。本文对羟氯喹在IgA肾病中应用的研究进展进行综述,为治疗IgA肾病提供新的治疗方案与思路。Hydroxychloroquine is a new type of antimalarial drug developed on the basis of chloroquine.At present,some studies have shown that hydroxychloroquine,as a new adjuvant immune regulator,can effectively reduce the proteinuria in patients with IgA nephropathy.IgA nephropathy is a group of clinical syndromes with IgA deposition in the glomerular mesangial region as the main immunopathological features.There is no specific treatment drug because of its complex pathogenesis.There is no specific therapy for IgA nephropathy at present either.This article systematically reviewed the research progress in the application of hydroxychloroquine in IgA nephropathy to provide a new treatment plan and thinking for IgA nephropathy.

关 键 词：羟氯喹 IGA肾病 自身免疫性疾病 免疫抑制剂 

分 类 号：R692.31[医药卫生—泌尿科学] R96[医药卫生—外科学]